Miriam Moscovitch-Lopatin Photo
Miriam Moscovitch-Lopatin
Harvard Medical School
Boston
Biography
Miriam Moscovitch-Lopatin, PhD, PMP: NCRI Biorepository Lab Supervisor, Neurology at Massachusetts General Hospital Assistant; Instructor in Neuroscience at Harvard Medical School. Dr. Moscovitch-Lopatin was the Program Manager for the Huntington’s Disease (HD) Biomarkers Program and directed proteomic biomarkers translational research, validation, and GLP deployment in clinical studies, as well as major aspects of the MGH’ HD biorepository. Her major focus has been measuring different species of mutant and normal Htt proteins in tissues and biofluids from preclinical and multicenter clinical trials. She has demonstrated the feasibility of using huntingtin (including the novel detection of oligomeric mutant huntingtin -mtHtt) as a pharmacodynamic marker and showed that CSF and plasma levels of several mtHtt species are highly correlated with each other and with some clinical outcomes. She recently co-developed with scientists at Quanterix the first ultra-sensitive Simoa assay for quantifying low levels of BDNF in CSF samples from HD patients for use in BDNF stem cell repletion therapy. Prior to her current position, Dr. Lopatin directed the development of qualification and release of personalized vaccines against Follicular Non-Hodgkin’s Lymphoma at Biovest/BioVax and conducted pre-clinical research in transplantation immunology as an Instructor in Medicine at Harvard Medical School/ BIDMC. Dr. Moscovitch-Lopatin holds a Ph.D. in Immunology from the Weizmann Institute, Rehovot, and a BSc and MSc in Life Sciences and Microbiology/Immunology from the Hebrew University, Jerusalem, Israel and she has a Project Management Profesional (PMP) certification.
Research Interests
Miriam Moscovitch-Lopatin, PhD, PMP: NCRI Biorepository Lab Supervisor, Neurology at Massachusetts General Hospital Assistant; Instructor in Neuroscience at Harvard Medical School. Dr. Moscovitch-Lopatin was the Program Manager for the Huntington’s Disease (HD) Biomarkers Program and directed proteomic biomarkers translational research, validation, and GLP deployment in clinical studies, as well as major aspects of the MGH’ HD biorepository. Her major focus has been measuring different species of mutant and normal Htt proteins in tissues and biofluids from preclinical and multicenter clinical trials. She has demonstrated the feasibility of using huntingtin (including the novel detection of oligomeric mutant huntingtin -mtHtt) as a pharmacodynamic marker and showed that CSF and plasma levels of several mtHtt species are highly correlated with each other and with some clinical outcomes. She recently co-developed with scientists at Quanterix the first ultra-sensitive Simoa assay for quantifying low levels of BDNF in CSF samples from HD patients for use in BDNF stem cell repletion therapy. Prior to her current position, Dr. Lopatin directed the development of qualification and release of personalized vaccines against Follicular Non-Hodgkin’s Lymphoma at Biovest/BioVax and conducted pre-clinical research in transplantation immunology as an Instructor in Medicine at Harvard Medical School/ BIDMC. Dr. Moscovitch-Lopatin holds a Ph.D. in Immunology from the Weizmann Institute, Rehovot, and a BSc and MSc in Life Sciences and Microbiology/Immunology from the Hebrew University, Jerusalem, Israel and she has a Project Management Profesional (PMP) certification.

Relevant Speakers

Upcoming Events
View All

Copyright © 2017-2018 Allied Academies, All Rights Reserved.